라임병 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Lyme Disease Market Outlook

Thelansis's "Lyme Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lyme Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lyme Disease Overview

Lyme disease, caused by Borrelia burgdorferi transmitted through Ixodes tick bites, remains the most prevalent vector-borne illness across North America and Europe, with incidence climbing due to climate-driven tick range expansion. Diagnosis relies on clinical presentation and two-tier serology, while early-stage infection is typically curable with doxycycline or amoxicillin; however, delayed treatment can progress to debilitating neurological, cardiac, and arthritic complications, and post-treatment Lyme disease syndrome remains poorly understood. Pfizer and Valneva's investigational vaccine candidate PF-07307405 (LB6V, formerly VLA15) demonstrated 73-75% efficacy in the Phase 3 VALOR trial announced in March 2026, with regulatory submissions to the FDA and EMA planned this year, positioning it as the first prophylactic option since LYMErix's 2002 withdrawal and a major commercial catalyst.

Key Highlights

• In Germany, incident Lyme disease cases are projected to increase from 56,330 in 2025 to 57,357 by 2035.
• Lyme disease is the most common tick-borne bacterial infection, with early diagnosis being critical to prevent long-term complications.
• Delayed or inadequate treatment may lead to persistent neurological, cardiac, and musculoskeletal manifestations.
• Significant unmet need remains for improved diagnostics and therapies for persistent or difficult-to-treat disease.

Market Overview

• The France Lyme disease market is projected to grow from $70M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnostic testing
• Ongoing development of novel anti-infective therapies and vaccines
• Future growth will depend on advancements in early diagnosis, preventive strategies, and more effective treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)